Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 2, 2026Journal of Clinical Psychopharmacology

Efficacy and Safety of Alpha-Lipoic Acid as an Adjunctive Therapy in Schizophrenia

View Full Paper
Ask AI
Bookmark
Share

Authors

GTGabriel Caruso Novaes TudellaMPMaria Antônia Oliveira Machado PereiraAKAugusto Utida Klostermann

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates ALA's effects on metabolic and psychiatric outcomes in schizophrenia, suggesting further research is needed.

Key Points

  • To assess the efficacy and safety of alpha-lipoic acid as an adjunctive therapy in schizophrenia.
  • Systematic review of human studies on alpha-lipoic acid in schizophrenia.
  • Conducted meta-analyses to pool results from identified studies.
  • Included eight studies with a total of 165 participants.
  • ALA showed no significant improvements in PANSS scores overall but some isolated improvements in small subsets.
  • RCT subgroup analysis indicated a reduction in BMI; overall analysis did not show significant effects.
  • No substantial differences were found between ALA and placebo regarding adverse events or discontinuation rates.

Cite This Study

Tudella et al. (2026) studied this question.

synapsesocial.com/papers/6a6eeabf1b0468a7eeab3357https://doi.org/10.1097/jcp.0000000000002231
View Full Paper
Ask AI
Bookmark
Share